Hemispherx Biopharma, Inc. to Present at Biotech Showcase™ 2018


ORLANDO, Fla., Dec. 29, 2017 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB), focused on pharmaceutical research, today announced, that it will be presenting at the Biotech Showcase™ 2018. The conference will be held January 8-10, 2018 at the Hilton San Francisco Union Square. Chief Executive Officer, Thomas K. Equels, M.S. J.D., will give the presentation and meet with investors.
Hemispherx has two flagship products: Alferon N Injection® and the experimental therapeutic Ampligen®. The Company also has six orphan drug designations with four in the U.S. and two in the European Union.Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences.To view the webcasting after the conference, please use this link: https://event.webcasts.com/starthere.jsp?ei=1176628&tp_key=1520205446About Hemispherx Biopharma, Inc.Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutics Ampligen®.  Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome.  Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because Ampligen® is experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials.The FDA approval of Alferon N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older.  The Company’s Alferon® N approval in Argentina includes the use of Alferon N Injection® (under the brand name “Naturaferon”) for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection.The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.CONTACTHemispherx Biopharma
Phone Number: 800-778-4042
Email: [email protected]  

Powered by WPeMatico